We’ve embedded our predictive model in a partner dashboard so collaborators can assess their chemistries for potential neurotoxicity. Read the full press release: ir.lunaibioworks.com/news/news-de...

We’re committed to responsible AI: advancing biodefense and public health applications while managing dual-use risks.

By integrating behavioral zebrafish profiling, we can observe real-time effects and rapidly rank candidates – moving from months to days for initial screening.

Our platform combines chemical feature analysis and machine learning to predict AChE inhibition with high accuracy (0.94 AUROC), helping triage potential threats and prioritize follow-up.

We’re using AI and zebrafish data to help detect neurotoxic compounds targeting acetylcholinesterase (AChE) and support defense and public health. #Biodefense #Neurotoxicity #AChE

🔗 Read the paper: www.nature.com/articles/s41... | Press release: www.newswire.com/news/landmar... #Duchenne #Biomarkers #Proteomics

This collaboration with Leiden University Medical Center, Parent Project Muscular Dystrophy, and @ufresearch.bsky.social demonstrates how data-driven science can transform clinical trial design and patient management in rare diseases.

Key biomarkers such as RGMA, ART3, and ANTXR2 were strongly associated with disease milestones like loss of ambulation, paving the way for improved monitoring and precision care.

Using over 700 serum samples and the 7K SomaScan proteomics platform, researchers found 294 proteins linked to muscle performance – one of the largest DMD proteomics efforts to date.

We are proud to announce that BioSymetrics (a @lunaibioworks.bsky.social company), Leiden University Medical Center, and @ufresearch.bsky.social have co-authored a new Nature Communications study identifying serum proteins that predict disease progression in Duchenne muscular dystrophy (DMD).

Together, we’re developing the Alzheimer’s Early Intervention Inflammatory Biomarker (AEIIB) panel – a first-of-its-kind approach for Alzheimer’s to predict and prevent disease progression. Learn more: www.einpresswire.com/article/4913...

We’re partnering with Moleculera Biosciences to detect Alzheimer’s years before symptoms appear. Using AI-driven analytics with novel neuroinflammatory biomarkers, we’re shifting diagnostics from reactive to proactive. #EarlyDetection #PrecisionMedicine #Alzheimers

We’re just getting started. Follow our journey here, on our website (www.lunaibioworks.com), and on LinkedIn (www.linkedin.com/company/luna...). #AIDrugDiscovery #Phenomics #PrecisionMedicine #FutureOfMedicine

Guided by science, powered by AI – we’re building a future where therapies emerge faster, safer, and with greater precision than ever before.

From oncology to neurology to biosecurity, our tech finds what others miss: 🎯 therapeutic targets • 🧬 patient stratification • 🧠 safety & efficacy insights

We unite prediction and proof, confirming discoveries in living systems to accelerate the path from idea to impact.

Hello! 👋 We’re Lunai Bioworks. Decoding life. Discovering cures. Our AI-powered phenomics platform captures disease in motion, decoding biology at scale to bring clarity to complexity.